Company news

Sutro Biopharma, Inc. news in 2021

Sutro Biopharma, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

December 26, 2021

Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors

November 16, 2021

Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones

November 9, 2021

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China

October 11, 2021

Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck

September 29, 2021

Sutro Biopharma Announces Expansion of Leadership Team

September 15, 2021

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

August 17, 2021

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones

August 8, 2021

Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer

August 8, 2021

Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany

May 31, 2021

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021

May 18, 2021

Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones

May 6, 2021

Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer

April 19, 2021

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck

April 14, 2021

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board

March 21, 2021

Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones

March 17, 2021

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

January 20, 2021

Decks in 2021